These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 9862427)

  • 1. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease.
    El-Agnaf OM; Jakes R; Curran MD; Wallace A
    FEBS Lett; 1998 Nov; 440(1-2):67-70. PubMed ID: 9862427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments.
    El-Agnaf OM; Jakes R; Curran MD; Middleton D; Ingenito R; Bianchi E; Pessi A; Neill D; Wallace A
    FEBS Lett; 1998 Nov; 440(1-2):71-5. PubMed ID: 9862428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
    Conway KA; Harper JD; Lansbury PT
    Biochemistry; 2000 Mar; 39(10):2552-63. PubMed ID: 10704204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein.
    Li J; Uversky VN; Fink AL
    Biochemistry; 2001 Sep; 40(38):11604-13. PubMed ID: 11560511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
    Conway KA; Harper JD; Lansbury PT
    Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro.
    Giasson BI; Uryu K; Trojanowski JQ; Lee VM
    J Biol Chem; 1999 Mar; 274(12):7619-22. PubMed ID: 10075647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.
    Lee MK; Stirling W; Xu Y; Xu X; Qui D; Mandir AS; Dawson TM; Copeland NG; Jenkins NA; Price DL
    Proc Natl Acad Sci U S A; 2002 Jun; 99(13):8968-73. PubMed ID: 12084935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein.
    Jo E; Fuller N; Rand RP; St George-Hyslop P; Fraser PE
    J Mol Biol; 2002 Jan; 315(4):799-807. PubMed ID: 11812148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.
    Kotzbauer PT; Giasson BI; Kravitz AV; Golbe LI; Mark MH; Trojanowski JQ; Lee VM
    Exp Neurol; 2004 Jun; 187(2):279-88. PubMed ID: 15144854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation.
    Narhi L; Wood SJ; Steavenson S; Jiang Y; Wu GM; Anafi D; Kaufman SA; Martin F; Sitney K; Denis P; Louis JC; Wypych J; Biere AL; Citron M
    J Biol Chem; 1999 Apr; 274(14):9843-6. PubMed ID: 10092675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
    El-Agnaf OM; Paleologou KE; Greer B; Abogrein AM; King JE; Salem SA; Fullwood NJ; Benson FE; Hewitt R; Ford KJ; Martin FL; Harriott P; Cookson MR; Allsop D
    FASEB J; 2004 Aug; 18(11):1315-7. PubMed ID: 15180968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease.
    Wood SJ; Wypych J; Steavenson S; Louis JC; Citron M; Biere AL
    J Biol Chem; 1999 Jul; 274(28):19509-12. PubMed ID: 10391881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro.
    Mishizen-Eberz AJ; Guttmann RP; Giasson BI; Day GA; Hodara R; Ischiropoulos H; Lee VM; Trojanowski JQ; Lynch DR
    J Neurochem; 2003 Aug; 86(4):836-47. PubMed ID: 12887682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.
    Conway KA; Lee SJ; Rochet JC; Ding TT; Williamson RE; Lansbury PT
    Proc Natl Acad Sci U S A; 2000 Jan; 97(2):571-6. PubMed ID: 10639120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein.
    Du HN; Tang L; Luo XY; Li HT; Hu J; Zhou JW; Hu HY
    Biochemistry; 2003 Jul; 42(29):8870-8. PubMed ID: 12873148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic filaments assembled from C-terminally truncated alpha-synuclein.
    Crowther RA; Jakes R; Spillantini MG; Goedert M
    FEBS Lett; 1998 Oct; 436(3):309-12. PubMed ID: 9801138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein.
    Cole NB; Murphy DD; Grider T; Rueter S; Brasaemle D; Nussbaum RL
    J Biol Chem; 2002 Feb; 277(8):6344-52. PubMed ID: 11744721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils.
    Lashuel HA; Petre BM; Wall J; Simon M; Nowak RJ; Walz T; Lansbury PT
    J Mol Biol; 2002 Oct; 322(5):1089-102. PubMed ID: 12367530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro.
    Cohlberg JA; Li J; Uversky VN; Fink AL
    Biochemistry; 2002 Feb; 41(5):1502-11. PubMed ID: 11814343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation.
    Serpell LC; Berriman J; Jakes R; Goedert M; Crowther RA
    Proc Natl Acad Sci U S A; 2000 Apr; 97(9):4897-902. PubMed ID: 10781096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.